Compare RICK & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RICK | CBIO |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.0M | 198.9M |
| IPO Year | 1995 | N/A |
| Metric | RICK | CBIO |
|---|---|---|
| Price | $24.85 | $13.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $98.00 | $27.17 |
| AVG Volume (30 Days) | 88.4K | ★ 123.2K |
| Earning Date | 02-09-2026 | 02-23-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ 252.84 | N/A |
| EPS | ★ 1.86 | N/A |
| Revenue | ★ $281,738,000.00 | N/A |
| Revenue This Year | $3.62 | N/A |
| Revenue Next Year | $8.86 | N/A |
| P/E Ratio | $13.46 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.88 | $9.81 |
| 52 Week High | $57.99 | $21.40 |
| Indicator | RICK | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 61.07 |
| Support Level | $24.04 | $10.56 |
| Resistance Level | $27.01 | $14.71 |
| Average True Range (ATR) | 1.13 | 0.86 |
| MACD | 0.06 | 0.35 |
| Stochastic Oscillator | 43.13 | 72.68 |
RCI Hospitality Holdings Inc through its subsidiaries owns and operates establishments that offer live adult entertainment, restaurant, and or bar operations. It also owns and operates a communication company serving the adult nightclub industry. The company's operating business segments are Nightclubs, Bombshells, and Others. It operates nightclubs through the following brands Rick's Cabaret, Vivid Cabaret, Tootsie's Cabaret, Club Onyx, and Jaguars Club. In the Bombshells segment, the company is building a chain of Restaurants and Sports Bars in Dallas, Austin, and Houston, Texas. It derives the majority of revenue from the Nightclubs segment that engages in the sale of alcoholic beverages, food, and merchandise items; service in the form of cover charges, dance fees, and room rentals.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.